Loading
companiesCompany
Kiyatec
Kiyatec grows a patient's tumour cells in 3D culture and tests drugs on them, with a focus on ovarian, breast, glioblastoma and rare tumours.
Overview
Kiyatec's ex vivo 3D cell culture platform predicts which drugs a patient's tumour will respond to by exposing living tumour cells to candidate therapies, and it has published clinical correlation studies in glioblastoma and ovarian cancer. Physician-ordered.
Similar pages
- Company2cureX
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanyCure-First
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanySageMedic
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanySpeciCare
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanyTravera
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyFirst Ascent Biomedical
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyKYAN Technologies
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyStoreMyTumor
Shares Functional (ex vivo) drug testing and the tag fcct-directory.